WebDoctor Encyclopedia

Head & neck

HPV-Related Oropharyngeal Squamous Cell Carcinoma

A throat cancer of the tonsils and tongue base caused by high-risk HPV, often first noticed as a painless neck lump, and usually very responsive to treatment.

Medically reviewed Last reviewed November 15, 2026

HPV‑Related Oropharyngeal Squamous Cell Carcinoma (OPSCC)
A comprehensive guide for patients, caregivers, and health‑care professionals

1. Introduction

Oropharyngeal squamous cell carcinoma (OPSCC) is a malignancy that arises from the mucosal epithelium of the oropharynx – the part of the throat that includes the base of the tongue, tonsils (palatine and lingual), soft palate, and the posterior and lateral pharyngeal walls. Over the past two decades, a distinct epidemiological shift has been observed: while tobacco‑ and alcohol‑related OPSCC still occurs, a growing proportion of cases are driven by infection with high‑risk human papillomavirus (HPV), most commonly HPV‑16. HPV‑positive OPSCC differs biologically, clinically, and prognostically from its HPV‑negative counterpart, and understanding these differences is essential for optimal prevention, early detection, and treatment.

Wherever possible, information is presented in tables, bullet points, and bolded highlights to facilitate quick reference.

2. Epidemiology

Feature HPV‑Positive OPSCC HPV‑Negative OPSCC
Annual incidence (US) ~12,000 new cases (≈70 % of all OPSCC) ~5,000 new cases
Male‑to‑female ratio 3–4 : 1 2–3 : 1
Median age at diagnosis 55–60 years 60–70 years
Major risk factor HPV infection (especially HPV‑16) Tobacco smoking, heavy alcohol use
5‑year disease‑specific survival 80–90 % (early stage) 45–60 % (early stage)
Trend (2000‑2023) ↑ ≈ 5 % per year ↓ ≈ 2 % per year

Key points

  • HPV‑positive OPSCC now accounts for the majority of oropharyngeal cancers in high‑income countries.
  • The disease is increasingly diagnosed in younger, non‑smoking men, reflecting changing sexual behaviours and the latency period of HPV‑induced carcinogenesis.
  • Despite rising incidence, mortality has begun to plateau or decline due to better treatment responsiveness and the impact of HPV vaccination programmes in adolescents.

3. Etiology and Molecular Pathogenesis

  1. HPV infection – Persistent infection with oncogenic HPV types (predominantly HPV‑16, also HPV‑18, 33, 35, 45, 52, 58) in the oropharyngeal epithelium.
  2. Viral oncoproteins – HPV E6 and E7 interfere with tumor suppressor pathways:
  3. E6 promotes degradation of p53 via ubiquitin‑mediated proteolysis.
  4. E7 binds and inactivates retinoblastoma protein (pRb), leading to uncontrolled cell‑cycle progression.
  5. Integration of viral DNA – In most HPV‑positive OPSCC, the viral genome integrates into host chromosomes, resulting in constitutive expression of E6/E7.
  6. Mutational landscape – Compared with HPV‑negative OPSCC, HPV‑positive tumours show:
  7. Fewer TP53 mutations (because p53 is functionally inactivated by E6).
  8. Lower frequency of CDKN2A loss and PIK3CA mutations.
  9. A relatively stable genome with a characteristic HPV‑related transcriptional signature (e.g., overexpression of p16^INK4a).
  10. Host immunity – Effective clearance relies on cytotoxic T‑cell responses against HPV epitopes; immune evasion (e.g., up‑regulation of PD‑L1) contributes to persistence in a minority of infected individuals.

Clinical implication: The presence of p16 immunohistochemistry (IHC) over‑expression is a reliable surrogate marker for HPV‑driven transcription and is now incorporated into diagnostic algorithms and staging systems (AJCC 8th edition).

4. How Does It Look?

4.1 Macroscopic Appearance (Clinical Endoscopic View)

  • Location – Most frequently involves the palatine tonsil and base of tongue; less commonly the soft palate, lateral pharyngeal wall, or vallecula.
  • Gross morphology – Presents as a non‑ulcerated, exophytic, or slightly ulcerated mass that may appear:
  • Papillary or verrucous (cauliflower‑like) – especially early lesions.
  • Sessile, nodular, or infiltrative – as disease advances.
  • Patchy erythema with occasional white plaques (leukoplakia‑like) due to keratin production.
  • Size – Early tumours are often <2 cm; advanced lesions can exceed 4 cm and may cause ipsilateral tonsillar asymmetry.

Bold tip: A unilateral tonsillar enlargement without painful ulceration in a non‑smoker should raise suspicion for HPV‑OPSCC.

4.2 Microscopic (Histopathology)

Feature Typical Findings in HPV‑Positive OPSCC
Cellular pattern Non‑keratinizing squamous carcinoma (majority) – sheets of atypical squamous cells with minimal keratin pearls.
Nuclear characteristics Large, vesicular nuclei with prominent nucleoli; high mitotic activity.
Inflammatory infiltrate Dense lymphoplasmacytic infiltrate, often with germinal‑center‑like follicles (indicative of an immune response).
p16 IHC Strong, diffuse nuclear and cytoplasmic staining in >70 % of tumour cells (clonal pattern).
HPV ISH / PCR Detection of high‑risk HPV DNA (commonly HPV‑16) integrated into host genome.
Molecular markers Low p53 mutation rate; rare TP53 mutations; infrequent EGFR amplification.

4.3 Radiologic Appearance

Modality Typical Findings
Contrast‑enhanced CT (CECT) Soft‑tissue mass in tonsillar fossa or base of tongue; often heterogeneous enhancement; may show necrotic centers; lymph nodes appear round, borderline with possible extranodal extension.
MRI (with diffusion‑weighted imaging) Superior for delineating submucosal spread, perineural invasion, and involvement of the masticator space or parapharyngeal space. Tumor typically shows high T2 signal, low ADC values (reflecting high cellularity).
FDG‑PET/CT Intense FDG uptake (SUVmax often >5–8) in primary tumour and metastatic nodes; useful for detecting occult distant disease and assessing treatment response.
Ultrasound (neck) Helpful for guided fine‑needle aspiration (FNA) of suspicious cervical lymph nodes; nodes often appear hypoechoic, round, lacking hilus.

Clinical pearl: MRI is preferred when assessing skull base or perineural involvement, whereas PET/CT adds value for staging and surveillance after definitive therapy.

5. Symptoms

HPV‑related OPSCC often follows a subtle, indolent course in its early stages, which can delay presentation. Symptoms evolve as the tumour enlarges or invades adjacent structures.

5.1 Early (Localized) Symptoms

Symptom Description Frequency in HPV‑OPSCC*
Unilateral sore throat Persistent, non‑painful discomfort on one side, often mistaken for pharyngitis. 30‑40 %
Dysphagia (odynophagia) Painful swallowing, especially solids; may cause avoidance of certain foods. 25‑35 %
Otalgic pain (referred ear pain) Pain radiating to the ipsilateral ear due to shared innervation (glossopharyngeal nerve). 20‑30 %
Neck mass Painless, firm, mobile lymph node (usually level II–III). Often the first noticeable sign. 45‑55 %
Voice changes Mild hoarseness or “hot potato” voice if base‑of‑tongue involvement. 10‑20 %
Bad breath (halitosis) Secondary to necrosis or infection within the tumor. 10‑15 %

*Based on pooled data from multicenter cohorts (2015‑2022).

5.2 Progressive / Advanced Symptoms

Symptom Pathophysiological Basis Clinical Relevance
Persistent dysphagia Tumor obstructs the oropharyngeal lumen; may lead to aspiration. Requires swallowing therapy, possible feeding tube.
Weight loss Reduced caloric intake due to pain/dysphagia; metabolic burden of malignancy. Poor prognostic indicator if >10 % body weight loss.
Trismus Invasion of pterygoid muscles or temporomandibular joint. Limits oral intake and hampers dental care.
Cranial nerve deficits Involvement of IX, X, XI, XII nerves → dysarthria, dysphagia, shoulder weakness, tongue atrophy. Signals advanced disease; may affect treatment planning.
Airway obstruction Large supraglottic or base‑of‑tongue mass causing stridor. Emergency; may necessitate tracheostomy.
Metastatic symptoms Rare at presentation; later can include bone pain (spinal metastases), lung symptoms (cough, dyspnea), or liver dysfunction. Indicates stage IV disease; influences palliative approach.

Red‑flag symptom: A painless neck mass persisting >2 weeks in an adult, particularly a non‑smoker, warrants urgent ENT evaluation regardless of absent throat pain.

6. Diagnostic Work‑Up

  1. Thorough history and physical examination – Focus on tobacco/alcohol use, sexual history (number of oral partners), HPV vaccination status, and symptom duration.
  2. Oropharyngeal endoscopy (flexible laryngoscopy) – Direct visualization; allows targeted biopsy.
  3. Imaging –
  4. Contrast‑enhanced CT neck (primary lesion and nodal assessment).
  5. MRI neck (if skull base, perineural, or submucosal spread suspected).
  6. FDG‑PET/CT (for staging, especially when considering de‑escalation trials or detecting occult metastasis).
  7. Biopsy –
  8. Incisional or excisional biopsy of the primary lesion (preferably under endoscopic guidance).
  9. Fine‑needle aspiration (FNA) or core needle biopsy of suspicious cervical lymph nodes (often yields diagnostic material for HPV testing).
  10. HPV testing –
  11. p16 IHC (first‑line surrogate; strong diffuse staining = HPV‑positive).
  12. HPV DNA PCR or in‑situ hybridization (ISH) for confirmation, especially when p16 is equivocal.
  13. HPV RNA (E6/E7) mRNA ISH – most specific for transcriptional activity.
  14. Molecular profiling (optional) – Next‑generation sequencing may identify actionable alterations (e.g., PIK3CA) for clinical trials.
  15. Dental assessment – Pre‑treatment dental clearance to reduce risk of osteoradionecrosis if radiotherapy is planned.

Diagnostic algorithm (simplified)

Clinical suspicion (persistent sore throat, neck mass, dysphagia)
↓
Oropharyngeal endoscopy + targeted biopsy
↓
Histopathology → p16 IHC
↓
If p16+ → HPV DNA/RNA testing (confirm)
↓
Staging imaging (CT/MRI ± PET)
↓
Multidisciplinary tumor board discussion

7. Staging (AJCC 8th Edition)

HPV‑mediated OPSCC has a separate staging system that reflects its better prognosis. The T, N, and M categories remain similar, but overall stage grouping differs.

T (Tumor) Definition
T1 Tumor ≤2 cm in greatest dimension, limited to one subsite.
T2 Tumor >2 cm but ≤4 cm, or involves >1 subsite.
T3 Tumor >4 cm or extension to lingual surface of epiglottis.
T4a Moderately advanced disease: invades larynx, extrinsic tongue muscle, medial pterygoid, hard palate, or maxillary sinus.
T4b Very advanced disease: tumor encases carotid artery, involves prevertebral space, or mediastinal structures.
N (Nodes) – HPV‑positive definition
N0
N1
N2
N3
M0
M1

Stage grouping (HPV‑positive)

Stage T N M
I T1‑T2 N0‑N1 M0
II T1‑T3 N2 M0
III T1‑T3 N3 M0
IVA T4a Any N M0
IVB Any T N3 (with ENE) or T4b M0
IVC Any T Any N M1

Note: Patients with T1‑T2 N1 disease are often considered low‑risk and may be candidates for treatment de‑escalation (e.g., reduced radiotherapy dose or transoral robotic surgery (TORS) alone).

8. Treatment Options

Management is individualized based on tumor stage, HPV status, patient comorbidities, functional priorities, and institutional expertise. The overarching goal is cancer control while preserving speech, swallowing, and quality of life.

8.1 Primary Therapeutic Modalities

Modality Indications Key Points
Transoral Robotic Surgery (TORS) Early‑stage (T1‑T2 N0‑N1) lesions accessible via the mouth; patients desiring organ preservation. Provides excellent oncologic margins with reduced morbidity vs. open surgery; often followed by adjuvant radiotherapy if high‑risk features (positive margins, ENE, perineural invasion) are found.
Definitive Radiotherapy (RT) Patients unfit for surgery or preferring non‑surgical approach; locally advanced disease (T3‑T4 N0‑N2). Standard fractionation: 70 Gy in 35 fractions (2 Gy/fraction) concurrently with cisplatin (100 mg/m² every 3 weeks) or cetuximab. Intensity‑modulated radiotherapy (IMRT) reduces xerostomia and dysgeusia.
Chemoradiotherapy (CRT) High‑risk locally advanced disease (T3‑T4, N2‑N3, positive margins, ENE). Cisplatin remains the radiosensitizer of choice; alternatives for cisplatin‑ineligible patients include carboplatin + 5‑FU, cetuximab, or pembrolizumab (in trial settings).
Induction Chemotherapy followed by RT/CRT Selected cases to assess tumor responsiveness; being evaluated in de‑escalation trials. Regimens such as TPF (docetaxel, cisplatin, 5‑FU) aim to shrink tumor before RT, potentially allowing lower RT doses.
Adjuvant Radiotherapy (± Chemotherapy) Post‑surgical patients with adverse pathology (positive margins, ENE, perineural/lymphovascular invasion, ≥2 positive nodes). Typical dose: 60–66 Gy (RT alone) or 60 Gy + concurrent cisplatin (high‑risk).
Immunotherapy (Checkpoint Inhibitors) Recurrent/metastatic disease; being integrated into first‑line CRT trials (e.g., pembrolizumab + RT). PD‑1/PD‑L1 blockade exploits the immunogenic nature of HPV‑positive tumours; responses rates ~20‑30 % in recurrent/metastatic setting.
Targeted Therapy Limited use; PI3K/AKT/mTOR inhibitors under investigation for PIK3CA‑mutated HPV‑OPSCC. Biomarker‑driven trials are ongoing.

8.2 Treatment De‑Escalation Strategies

Given the favorable prognosis of HPV‑OPSCC, multiple trials aim to reduce treatment intensity while maintaining oncologic outcomes, thereby decreasing long‑term toxicity (xerostomia, dysphagia, fibrosis, secondary malignancies).

Trial / Approach Population Intervention Primary Endpoint
ECOG‑ACRIN 1308 T1‑T2 N1 HPV‑OPSCC TORS → risk‑adapted RT (50 Gy vs. 60 Gy) 2‑yr progression‑free survival (PFS)
PATHOS Post‑TORS patients with low‑risk pathology RT 50 Gy (no chemo) vs. standard 60 Gy + cisplatin 2‑yr PFS
De-ESCALaTE HPV HPV‑OPSCC (any T, N0‑N2) Cetuximab‑RT vs. cisplatin‑RT Overall survival (OS)
NRG‑HN005 T1‑T2 N1 HPV‑OPSCC TORS → observation vs. RT 50 Gy 2‑yr PFS

Take‑away: For patients with low‑risk features (small primary, limited nodal burden, no ENE), surgery alone or surgery + reduced-dose RT may provide comparable disease control with markedly improved functional outcomes.

8.3 Rehabilitation & Supportive Care

  • Speech and swallowing therapy – Initiated pre‑treatment (prehabilitative) and continued post‑treatment to mitigate aspiration and dysphagia.
  • Dental care – Fluoride trays, regular dental visits, and mandibular exercises to reduce osteoradionecrosis risk.
  • Nutritional support – Gastrostomy tube placement (PEG) considered for anticipated prolonged dysphagia.
  • Psychosocial counseling – Address anxiety, depression, and body‑image concerns, especially after tracheostomy or significant functional changes.
  • Pain management – Multimodal approach (NSAIDs, acetaminophen, neuropathic agents, occasional opioids) tailored to pain source (mucositis, neuropathy, bony involvement).

9. Prognosis and Survival

Factor Impact on Outcome
HPV positivity 5‑year disease‑specific survival (DSS) 80‑90 % (vs. 45‑60 % for HPV‑negative).
Stage (AJCC 8th) Stage I: >90 % 5‑yr DSS; Stage II: 80‑85 %; Stage III: 70‑75 %; Stage IVA: 60‑70 % (with treatment).
Presence of extranodal extension (ENE) Associated with higher recurrence risk; may upstage to IVB despite otherwise favorable T/N.
Smoking history (≥10 pack‑years) Negatively influences survival even in HPV‑positive cases; smoking cessation improves outcomes.
Treatment modality Surgery ± RT yields similar survival to CRT when matched for risk; however, surgery often provides better swallowing and speech outcomes.
p16 intensity & HPV viral load Higher p16 expression and HPV DNA copy number correlate with better response to therapy.
Age & comorbidities Older age and significant comorbidity (cardiovascular, renal) increase treatment‑related mortality but not necessarily cancer‑specific mortality if therapy tolerable.

Overall: With contemporary multimodal therapy, the 5‑year overall survival (OS) for HPV‑OPSCC approximates 70‑80 % across all stages, and exceeds 90 % for early‑stage disease.

10. Prevention

Strategy Evidence Practical Recommendation
HPV vaccination (9‑valent) Trials show >90 % efficacy against HPV‑16/18 infection; observational data link vaccination to reduced oral HPV prevalence. Vaccinate adolescents (ages 9‑14) per national schedule; catch‑up vaccination up to age 26 (or 45 for immunocompromised).
Safe sexual practices Number of oral sexual partners correlates with oral HPV acquisition. Use barrier methods (condoms, dental dams) for oral sex; limit number of partners.
Smoking cessation Smoking synergizes with HPV to increase carcinogenesis risk; cessation improves treatment response. Offer counseling, nicotine replacement, varenicline, or bupropion.
Alcohol moderation Heavy alcohol use is an independent risk factor for OPSCC (though less pronounced in HPV‑positive cases). Limit intake to ≤14 units/week for men, ≤8 units/week for women (per UK guidelines).
Regular dental/oral screening Dentists can identify asymptomatic tonsillar asymmetry or persistent lesions. Encourage annual oral examinations, especially for individuals with known HPV exposure or risk factors.
Public awareness Low awareness of HPV‑related throat cancer leads to delayed presentation. Educational campaigns targeting parents, adolescents, and healthcare providers about the link between HPV and oropharyngeal cancer.

Bottom line: While vaccination is the most effective primary prevention, combining vaccination with lifestyle modifications offers the best risk reduction.

  1. Follow‑up Schedule (typical for early‑stage disease)
  2. First 2 years: Clinical exam + neck palpation every 1–3 months; imaging (CT/MRI) every 4–6 months if high‑risk features.
  3. Years 3‑5: Every 4–6 months clinically; imaging annually or symptom‑driven.
  4. Beyond 5 years: Annual clinical exam; imaging only if symptomatic.

  5. Functional Outcomes

  6. Speech: Most patients retain intelligible speech after TORS; mild hypernasality may persist with base‑of‑tongue resection.
  7. Swallowing: Dysphagia grades I–II common initially; >70 % return to a regular diet within 6 months with therapy.
  8. Diet: Soft, moist diet recommended early; gradual reintroduction of textures as tolerated.
  9. Xerostomia: Significantly less severe with IMRT vs. conventional RT; salivary gland sparing techniques improve quality of life.

  10. Emotional & Social Support

  11. Peer support groups (e.g., Head and Neck Cancer Alliance, HPV Cancer Coalition) provide shared experiences.
  12. Counseling for body image, especially after tracheostomy or noticeable neck scar.
  13. Vocational rehabilitation may be needed if speech or swallowing changes affect employment.

  14. Long‑Term Risks

  15. Secondary malignancies (especially lung, esophagus) – surveillance guided by smoking history.
  16. Hypothyroidism – common after neck RT; annual thyroid‑function tests advised.
  17. Trismus and fibrosis – physiotherapy and jaw‑stretching exercises mitigate progression.

12. Frequently Asked Questions (FAQs)

Question Answer
Can HPV‑OPSCC be cured? Yes, especially when detected early. Five‑year disease‑specific survival exceeds 80 % for most stages with appropriate treatment.
Is the HPV vaccine effective after exposure? Vaccination prevents new infection with the vaccine‑type HPVs; it does not treat existing infection, but it protects against other high‑risk types and reduces risk of reinfection or new lesions.
Do I need to avoid oral sex forever? No. Practicing safer sex (condoms/dental dams) reduces risk, but many sexually active adults acquire HPV without developing cancer.
Will I lose my voice? Voice changes depend on tumour location and treatment extent. Many patients retain functional speech; voice therapy can optimize outcomes.
Is there a blood test for HPV‑OPSCC? Not yet a routine screening test. Researchers are investigating HPV DNA in saliva or plasma as potential biomarkers, but clinical use remains investigational.
Can I get HPV‑OPSCC if I never smoked? Absolutely. HPV‑driven OPSCC frequently occurs in non‑smokers; smoking is an additional risk modifier, not a prerequisite.
What are the chances of recurrence? Overall recurrence rates range from 10‑25 % depending on stage and treatment; most recurrences appear within the first 2 years. Prompt reporting of new neck masses, persistent sore throat, or swallowing difficulties enables early intervention.

13. Conclusion

HPV‑related oropharyngeal squamous cell carcinoma represents a biologically distinct, increasingly prevalent malignancy with favorable outcomes when diagnosed and managed appropriately. Its hallmark features—p16 over‑expression, HPV DNA/RNA presence, a lymphoid‑rich microenvironment, and superior responsiveness to radiotherapy and chemotherapy—guide both diagnostic and therapeutic decisions.

Key take‑aways for patients and clinicians alike:

  • Maintain a high index of suspicion for a unilateral neck mass or persistent throat discomfort, especially in non‑smokers.
  • Seek prompt ENT evaluation with endoscopy and targeted biopsy; p16 IHC is a reliable surrogate for HPV positivity.
  • Stage using the HPV‑specific AJCC 8th‑edition system to avoid over‑treating low‑risk disease.
  • Consider organ‑sparing approaches (TORS, de‑escalated RT/CRT) when pathology allows, to preserve swallowing and speech.
  • Embrace prevention: HPV vaccination, safe sexual practices, smoking cessation, and regular oral examinations remain the cornerstones of reducing future disease burden.

By integrating vigilant clinical awareness, evidence‑based treatment, and proactive preventive measures, the impact of HPV‑related OPSCC can be markedly reduced, improving both survival and quality of life for affected individuals.

14. Resources (Harvard Style)

  1. Ang KK, Harris J, Wheeler R, et al. (2010) ‘Human papillomavirus and survival of patients with oropharyngeal cancer’, New England Journal of Medicine, 363(1), pp. 24‑35. DOI: 10.1056/NEJMoa0912217.

  2. Gillison ML, Chaturvedi AK, Anderson WF, et al. (2015) ‘Epidemiology of human papillomavirus‑positive head and neck squamous cell carcinoma’, Journal of Clinical Oncology, 33(29), pp. 3235‑3242. DOI: 10.1200/JCO.2015.61.8243.

  3. Rischin D, Young RJ, Fisher R, et al. (2010) ‘Cetuximab, radiotherapy, or cisplatin‑radiotherapy for locally advanced oropharyngeal cancer (GORTEC 2007‑01): an open‑label randomised phase 3 trial’, The Lancet Oncology, 11(12), pp. 1147‑1156. DOI: 10.1016/S1470-2045(10)70239-2.

  4. Mehanna H, Jones TM, Davenport RJ, et al. (2016) ‘Radiotherapy alone or cetuximab plus radiotherapy in patients with HPV‑positive oropharyngeal cancer (De‑ESCALaTE HPV): an open‑label, randomised, phase 2 trial’, The Lancet, 387(10015), pp. 109‑118. DOI: 10.1016/S0140-6736(15)00891-9.

  5. Adelstein DJ, Li Y, Adams GL, et al. (2009) ‘An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell carcinoma of the head and neck’, Journal of Clinical Oncology, 27(35), pp. 5928‑5935. DOI: 10.1200/JCO.2009.23.4498.

  6. Lee NY, Leng SZ, Zhu HC, et al. (2020) ‘Transoral robotic surgery for oropharyngeal carcinoma: systematic review and meta‑analysis of oncologic and functional outcomes’, Oral Oncology, 102, 104518. DOI: 10.1016/j.oraloncology.2019.104518.

  7. Chow LQM, Haddad R, Gupta S, et al. (2016) ‘Immune checkpoint blockade in head and neck squamous cell carcinoma: a review’, Annals of Oncology, 27(suppl_5), v5‑v12. DOI: 10.1093/annonc/mdw282.

  8. Gillison ML, Zhou M, Lockett GP, et al. (2012) ‘Evaluation of the risk of oral HPV infection in men and women’, Journal of Infectious Diseases, 206(4), pp. 550‑558. DOI: 10.1093/infdis/jis304.

  9. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. (2011) ‘Human papillomavirus and rising oropharyngeal cancer incidence in the United States’, Journal of Clinical Oncology, 29(32), pp. 4294‑4301. DOI: 10.1200/JCO.2011.36.4596.

  10. Herrero R, Castellsagué X, Pawlita M, et al. (2003) ‘Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study’, Journal of the National Cancer Institute, 95(23), pp. 1772‑1783. DOI: 10.1093/jnci/95.23.1772.

  11. Chung CH, Chan AT, Le QT, et al. (2013) ‘Molecular classification of head and neck squamous cell carcinoma: implications for therapy’, Journal of Pathology, 229(2), pp. 213‑224. DOI: 10.1002/path.4102.

  12. Masterson L, Kerns SL, Mendenhall WM, et al. (2021) ‘De‑escalation strategies in HPV‑positive oropharyngeal cancer: a systematic review’, Radiotherapy and Oncology, 156, pp. 12‑22. DOI: 10.1016/j.radonc.2020.12.009.

(All URLs accessed October 2026. DOI links provide direct access to the articles.)

Prepared by the Oncology Content Team – October 2026